Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study

Lignende værker

• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  af: Gommoll, Carl P., et al.
  Udgivet: (2014)
• A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder
  af: Shiovitz, Thomas, et al.
  Udgivet: (2014)
• A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
  af: Sambunaris, Angelo, et al.
  Udgivet: (2014)
• Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
  af: Montgomery, Stuart A., et al.
  Udgivet: (2014)
• Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
  af: Mathews, Maju, et al.
  Udgivet: (2015)